<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250411101140&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250411101140&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 11 Apr 2025 14:11:42 +0000</lastbuilddate>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Heart Has Intrinsic Ketogenic Capacity that Mediates NAD&lt;sup>;+&lt;/sup>; Therapy in HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40211954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11. doi: 10.1161/CIRCRESAHA.124.325550. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has overtaken heart failure with reduced ejection fraction as the leading type of heart failure globally and is marked by high morbidity and mortality rates, yet with only a single approved pharmacotherapy: SGLT2i (sodium-glucose co-transporter 2 inhibitor). A prevailing theory for the mechanism underlying SGLT2i is nutrient deprivation signaling, of which ketogenesis is a hallmark. However, it is unclear whether the canonical ketogenic enzyme, HMGCS2 (3-hydroxy-3-methylglutaryl-coenzyme A synthase 2), plays any cardiac role in HFpEF pathogenesis or therapeutic response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used human myocardium, human HFpEF and heart failure with reduced ejection fraction transcardiac blood sampling, an established murine model of HFpEF, ex vivo Langendorff perfusion, stable isotope tracing in isolated cardiomyocytes, targeted metabolomics, proteomics, lipidomics, and a novel cardiomyocyte-specific conditional HMGCS2-deficient model that we generated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrate, for the first time, the intrinsic capacity of the human heart to produce ketones via HMGCS2. We found that increased acetylation of HMGCS2 led to a decrease in the enzyme's specific activity. However, this was overcome by an increase in the steady-state levels of protein. Oxidized form of nicotinamide adenine dinucleotide repletion restored HMGCS2 function via deacetylation, increased fatty acid oxidation, and rescued cardiac function in HFpEF. Critically, using a conditional, cardiomyocyte-specific HMGCS2 knockdown murine model, we revealed that the oxidized form of nicotinamide adenine dinucleotide is unable to rescue HFpEF in the absence of cardiomyocyte HMGCS2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40211954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40211954</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325550>10.1161/CIRCRESAHA.124.325550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40211954</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yen Chin Koay</dc:creator>
<dc:creator>Bailey McIntosh</dc:creator>
<dc:creator>Yann Huey Ng</dc:creator>
<dc:creator>Yang Cao</dc:creator>
<dc:creator>XiaoSuo Wang</dc:creator>
<dc:creator>Yanchuang Han</dc:creator>
<dc:creator>Saki Tomita</dc:creator>
<dc:creator>Angela Yu Bai</dc:creator>
<dc:creator>Benjamin Hunter</dc:creator>
<dc:creator>Ashish Misra</dc:creator>
<dc:creator>Christopher M Loughrey</dc:creator>
<dc:creator>Paul G Bannon</dc:creator>
<dc:creator>Sean Lal</dc:creator>
<dc:creator>Aldons J Lusis</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>Mark Larance</dc:creator>
<dc:creator>John F O'Sullivan</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Heart Has Intrinsic Ketogenic Capacity that Mediates NAD&lt;sup>;+&lt;/sup>; Therapy in HFpEF</dc:title>
<dc:identifier>pmid:40211954</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325550</dc:identifier>
</item>
<item>
<title>Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40211947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11. doi: 10.1161/CIRCRESAHA.124.325310. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiometabolic heart failure with preserved ejection fraction (cHFpEF) is a highly prevalent and deadly condition. Histone 3 trimethylation at lysine 36 (H3k36me3)-a chromatin signature induced by the histone methyltransferase SETD2 (SET domain containing 2)-correlates with changes in gene expression in human failing hearts; however, its role remains poorly understood. This study investigates the role of SETD2 in cHFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Chromatin immunoprecipitation sequencing and RNA sequencing were used to investigate H3k36me3-related transcriptional regulation. Mice with cardiomyocyte-specific deletion of SETD2 (c-SETD2<sup>-/-</sup>) were generated and subjected to high-fat diet feeding and L-NAME treatment for 15 weeks to induce cHFpEF. Cardiac function and exercise tolerance were assessed by echocardiography and treadmill exhaustion test. A selective pharmacological inhibitor of SETD2, EZM0414, was also tested in cHFpEF mice. Mechanistic experiments were performed in cultured cardiomyocytes exposed to palmitic acid. SETD2 signaling and the effects of EZM0414 were also investigated in cardiomyocytes from patients with cHFpEF and control donors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SETD2 was upregulated in cHFpEF mouse hearts, and its chromatin mark H3k36me3 was involved in lipid metabolism and highly enriched on the promoter of the <i>Srebf1</i> gene, encoding for SREBP1 (sterol regulatory binding protein 1). SETD2 activation in cHFpEF led to SREBP1 upregulation, triglyceride accumulation, and lipotoxic damage. Of note, cardiomyocyte-specific deletion of SETD2 in mice prevented heart failure with preserved ejection fraction-related hypertrophy, diastolic dysfunction, and lung congestion while improving exercise tolerance. SETD2 deletion blunted H3K36me3 enrichment on <i>Srebf1</i> promoter, thus leading to a marked rewiring of the cardiac lipidome and restoration of autophagic flux. In vivo treatment with the SETD2 inhibitor EZM0414 recapitulated the effects of SETD2 deletion. Silencing of SETD2 in palmitic acid-treated cardiomyocytes prevented SREBP1 upregulation, whereas SETD2 overexpression mirrored lipotoxic damage. Finally, SETD2 was upregulated in left ventricle specimens from patients with cHFpEF while EZM0414 attenuated cardiomyocyte stiffness.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40211947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40211947</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325310>10.1161/CIRCRESAHA.124.325310</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40211947</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Sarah Costantino</dc:creator>
<dc:creator>Shafeeq A Mohammed</dc:creator>
<dc:creator>Samuele Ambrosini</dc:creator>
<dc:creator>Marialucia Telesca</dc:creator>
<dc:creator>Alessandro Mengozzi</dc:creator>
<dc:creator>Kaivalya Walavalkar</dc:creator>
<dc:creator>Era Gorica</dc:creator>
<dc:creator>Melissa Herwig</dc:creator>
<dc:creator>Loek van Heerebeek</dc:creator>
<dc:creator>Junyan Xia</dc:creator>
<dc:creator>Gergely Karsai</dc:creator>
<dc:creator>Thorsten Hornemann</dc:creator>
<dc:creator>Omer Dzemali</dc:creator>
<dc:creator>Raffaella Santoro</dc:creator>
<dc:creator>Qian Li</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>Nazha Hamdani</dc:creator>
<dc:creator>Francesco Paneni</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF</dc:title>
<dc:identifier>pmid:40211947</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325310</dc:identifier>
</item>
<item>
<title>Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40211944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 11. doi: 10.1161/CIRCULATIONAHA.124.072340. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Whole-exome sequencing identified a novel <i>DSC2</i> sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with <i>Dsc2</i> sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. <i>Dsc2</i> mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in <i>Dsc2</i> knock-out mice. In addition, effects of <i>Dsc2</i> mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>Dsc2</i>-deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified <i>Myl7</i> as the most downregulated gene in the right ventricles of <i>Dsc2</i>-deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. <i>Dsc2</i> mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in <i>Dsc2</i>-deficient mice. Reduced <i>DSC2</i> and <i>MLC2a</i> expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by <i>DSC2</i> loss of function, supported by human and mouse data. Loss of <i>Myl7</i> contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. <i>Dsc2</i> mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40211944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40211944</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072340>10.1161/CIRCULATIONAHA.124.072340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40211944</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yan Zou</dc:creator>
<dc:creator>Jing Lu</dc:creator>
<dc:creator>Zhipeng Lian</dc:creator>
<dc:creator>Jianguo Jia</dc:creator>
<dc:creator>Juan Shen</dc:creator>
<dc:creator>Qianhe Li</dc:creator>
<dc:creator>Jennifer Ming Jen Wong</dc:creator>
<dc:creator>Kejia Jin</dc:creator>
<dc:creator>Wendi Yan</dc:creator>
<dc:creator>Xinyue Ren</dc:creator>
<dc:creator>Yang Zhang</dc:creator>
<dc:creator>Chenxing Huang</dc:creator>
<dc:creator>Huanjie Yang</dc:creator>
<dc:creator>Feng Huang</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Junyu Zhai</dc:creator>
<dc:creator>Yamei Xu</dc:creator>
<dc:creator>Xialian Xu</dc:creator>
<dc:creator>Hang Yu</dc:creator>
<dc:creator>Yi Jin</dc:creator>
<dc:creator>Hui Gong</dc:creator>
<dc:creator>Jinzhong Lin</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Yuxiang Dai</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy</dc:title>
<dc:identifier>pmid:40211944</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072340</dc:identifier>
</item>
<item>
<title>Development of a miniature, bioresorbable, light-activated pacemaker</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40210756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 10. doi: 10.1038/s41569-025-01157-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40210756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40210756</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01157-8>10.1038/s41569-025-01157-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40210756</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Development of a miniature, bioresorbable, light-activated pacemaker</dc:title>
<dc:identifier>pmid:40210756</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01157-8</dc:identifier>
</item>
<item>
<title>No effect of cerebral embolic protection devices on stroke risk after TAVI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40210755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 10. doi: 10.1038/s41569-025-01156-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40210755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40210755</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01156-9>10.1038/s41569-025-01156-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40210755</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>No effect of cerebral embolic protection devices on stroke risk after TAVI</dc:title>
<dc:identifier>pmid:40210755</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01156-9</dc:identifier>
</item>
<item>
<title>Apolipoprotein B100 revisited</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40210754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 10. doi: 10.1038/s41569-025-01155-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40210754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40210754</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01155-w>10.1038/s41569-025-01155-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40210754</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Mia S Manojlovic</dc:creator>
<dc:creator>Melaku Taye Amogne</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Apolipoprotein B100 revisited</dc:title>
<dc:identifier>pmid:40210754</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01155-w</dc:identifier>
</item>
<item>
<title>Extensive N4 cytosine methylation is essential for Marchantia sperm function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40209706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>N4-methylcytosine (4mC) is an important DNA modification in prokaryotes, but its relevance and even its presence in eukaryotes have been mysterious. Here we show that spermatogenesis in the liverwort Marchantia polymorpha involves two waves of extensive DNA methylation reprogramming. First, 5-methylcytosine (5mC) expands from transposons to the entire genome. Notably, the second wave installs 4mC throughout genic regions, covering over 50% of CG sites in sperm. 4mC requires a methyltransferase...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 2:S0092-8674(25)00287-9. doi: 10.1016/j.cell.2025.03.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">N4-methylcytosine (4mC) is an important DNA modification in prokaryotes, but its relevance and even its presence in eukaryotes have been mysterious. Here we show that spermatogenesis in the liverwort Marchantia polymorpha involves two waves of extensive DNA methylation reprogramming. First, 5-methylcytosine (5mC) expands from transposons to the entire genome. Notably, the second wave installs 4mC throughout genic regions, covering over 50% of CG sites in sperm. 4mC requires a methyltransferase (MpDN4MT1a) that is specifically expressed during late spermiogenesis. Deletion of MpDN4MT1a alters the sperm transcriptome, causes sperm swimming and fertility defects, and impairs post-fertilization development. Our results reveal extensive 4mC in a eukaryote, identify a family of eukaryotic methyltransferases, and elucidate the biological functions of 4mC in reproductive development, thereby expanding the repertoire of functional eukaryotic DNA modifications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40209706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40209706</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.014>10.1016/j.cell.2025.03.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40209706</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>James Walker</dc:creator>
<dc:creator>Jingyi Zhang</dc:creator>
<dc:creator>Yalin Liu</dc:creator>
<dc:creator>Shujuan Xu</dc:creator>
<dc:creator>Yiming Yu</dc:creator>
<dc:creator>Martin Vickers</dc:creator>
<dc:creator>Weizhi Ouyang</dc:creator>
<dc:creator>Judit Tálas</dc:creator>
<dc:creator>Liam Dolan</dc:creator>
<dc:creator>Keiji Nakajima</dc:creator>
<dc:creator>Xiaoqi Feng</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Extensive N4 cytosine methylation is essential for Marchantia sperm function</dc:title>
<dc:identifier>pmid:40209706</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.014</dc:identifier>
</item>
<item>
<title>Engineered nucleocytosolic vehicles for loading of programmable editors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40209705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>Advanced gene editing methods have accelerated biomedical discovery and hold great therapeutic promise, but safe and efficient delivery of gene editors remains challenging. In this study, we present a virus-like particle (VLP) system featuring nucleocytosolic shuttling vehicles that retrieve pre-assembled Cas-effectors via aptamer-tagged guide RNAs. This approach ensures preferential loading of fully assembled editor ribonucleoproteins (RNPs) and enhances the efficacy of prime editing, base...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 3:S0092-8674(25)00288-0. doi: 10.1016/j.cell.2025.03.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Advanced gene editing methods have accelerated biomedical discovery and hold great therapeutic promise, but safe and efficient delivery of gene editors remains challenging. In this study, we present a virus-like particle (VLP) system featuring nucleocytosolic shuttling vehicles that retrieve pre-assembled Cas-effectors via aptamer-tagged guide RNAs. This approach ensures preferential loading of fully assembled editor ribonucleoproteins (RNPs) and enhances the efficacy of prime editing, base editing, trans-activators, and nuclease activity coupled to homology-directed repair in multiple immortalized, primary, stem cell, and stem-cell-derived cell types. We also achieve additional protection of inherently unstable prime editing guide RNAs (pegRNAs) by shielding the 3'-exposed end with Csy4/Cas6f, further enhancing editing performance. Furthermore, we identify a minimal set of packaging and budding modules that can serve as a platform for bottom-up engineering of enveloped delivery vehicles. Notably, our system demonstrates superior per-VLP editing efficiency in primary T lymphocytes and two mouse models of inherited retinal disease, highlighting its therapeutic potential.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40209705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40209705</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.015>10.1016/j.cell.2025.03.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40209705</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Julian Geilenkeuser</dc:creator>
<dc:creator>Niklas Armbrust</dc:creator>
<dc:creator>Emily Steinmaßl</dc:creator>
<dc:creator>Samuel W Du</dc:creator>
<dc:creator>Sebastian Schmidt</dc:creator>
<dc:creator>Eva Maria Hildegard Binder</dc:creator>
<dc:creator>Yuchun Li</dc:creator>
<dc:creator>Niklas Wilhelm Warsing</dc:creator>
<dc:creator>Stephanie Victoria Wendel</dc:creator>
<dc:creator>Florian von der Linde</dc:creator>
<dc:creator>Elisa Marie Schiele</dc:creator>
<dc:creator>Xiya Niu</dc:creator>
<dc:creator>Luisa Stroppel</dc:creator>
<dc:creator>Oleksandr Berezin</dc:creator>
<dc:creator>Tobias Heinrich Santl</dc:creator>
<dc:creator>Tanja Orschmann</dc:creator>
<dc:creator>Keith Nelson</dc:creator>
<dc:creator>Christoph Gruber</dc:creator>
<dc:creator>Grazyna Palczewska</dc:creator>
<dc:creator>Carolline Rodrigues Menezes</dc:creator>
<dc:creator>Eleonora Risaliti</dc:creator>
<dc:creator>Zachary J Engfer</dc:creator>
<dc:creator>Naile Koleci</dc:creator>
<dc:creator>Andrea Schmidts</dc:creator>
<dc:creator>Arie Geerlof</dc:creator>
<dc:creator>Krzysztof Palczewski</dc:creator>
<dc:creator>Gil Gregor Westmeyer</dc:creator>
<dc:creator>Dong-Jiunn Jeffery Truong</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineered nucleocytosolic vehicles for loading of programmable editors</dc:title>
<dc:identifier>pmid:40209705</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.015</dc:identifier>
</item>
<item>
<title>Long Noncoding RNA &lt;em>;MIR181A1HG&lt;/em>; Takes a Proinflammatory Driver's Seat in Atherosclerosis by Hijacking FOXP1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11;136(8):884-886. doi: 10.1161/CIRCRESAHA.125.326366. Epub 2025 Apr 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208929</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326366>10.1161/CIRCRESAHA.125.326366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208929</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>James A Oo</dc:creator>
<dc:creator>Timothy Warwick</dc:creator>
<dc:creator>Matthias S Leisegang</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Long Noncoding RNA &lt;em>;MIR181A1HG&lt;/em>; Takes a Proinflammatory Driver's Seat in Atherosclerosis by Hijacking FOXP1</dc:title>
<dc:identifier>pmid:40208929</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326366</dc:identifier>
</item>
<item>
<title>&lt;em>;TMEM&lt;/em>;-ing the Tide: Gene Therapy Holds Promise for ARVC5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11;136(8):845-847. doi: 10.1161/CIRCRESAHA.125.326367. Epub 2025 Apr 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208928</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326367>10.1161/CIRCRESAHA.125.326367</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208928</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Sandra Ratnavadivel</dc:creator>
<dc:creator>Matthew W Ellis</dc:creator>
<dc:creator>Farah Sheikh</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>&lt;em>;TMEM&lt;/em>;-ing the Tide: Gene Therapy Holds Promise for ARVC5</dc:title>
<dc:identifier>pmid:40208928</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326367</dc:identifier>
</item>
<item>
<title>Nuclear Receptors in Platelet Activation and Thrombosis in Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11;136(8):827-829. doi: 10.1161/CIRCRESAHA.125.326364. Epub 2025 Apr 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208927</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326364>10.1161/CIRCRESAHA.125.326364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208927</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yanki Yarman</dc:creator>
<dc:creator>Xuefei Zhao</dc:creator>
<dc:creator>Peisong Ma</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Nuclear Receptors in Platelet Activation and Thrombosis in Hypercholesterolemia</dc:title>
<dc:identifier>pmid:40208927</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326364</dc:identifier>
</item>
<item>
<title>Gut Instincts: The Gut Microbiome-Cardiovascular Inflammation Axis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208926/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11;136(8):806-808. doi: 10.1161/CIRCRESAHA.125.326363. Epub 2025 Apr 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208926/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208926</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326363>10.1161/CIRCRESAHA.125.326363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208926</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Jessie M Dalman</dc:creator>
<dc:creator>Emma R Blaustein</dc:creator>
<dc:creator>Coen van Solingen</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Gut Instincts: The Gut Microbiome-Cardiovascular Inflammation Axis</dc:title>
<dc:identifier>pmid:40208926</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326363</dc:identifier>
</item>
<item>
<title>Pathways and Molecular Mechanisms Governing LDL Receptor Regulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>Clearance of circulating plasma LDL (low-density lipoprotein) cholesterol by the liver requires hepatic LDLR (low-density lipoprotein receptor). Complete absence of functional LDLR manifests in severe hypercholesterolemia and premature atherosclerotic cardiovascular disease. Since the discovery of the LDLR 50 years ago by Brown and Goldstein, all approved lipid-lowering medications have been aimed at increasing the abundance and availability of LDLR on the surface of hepatocytes to promote the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11;136(8):902-919. doi: 10.1161/CIRCRESAHA.124.323578. Epub 2025 Apr 10.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clearance of circulating plasma LDL (low-density lipoprotein) cholesterol by the liver requires hepatic LDLR (low-density lipoprotein receptor). Complete absence of functional LDLR manifests in severe hypercholesterolemia and premature atherosclerotic cardiovascular disease. Since the discovery of the LDLR 50 years ago by Brown and Goldstein, all approved lipid-lowering medications have been aimed at increasing the abundance and availability of LDLR on the surface of hepatocytes to promote the removal of LDL particles from the circulation. As such a critical regulator of circulating and cellular cholesterol, it is not surprising that LDLR activity is tightly regulated. Despite over half a century's worth of study, there are still many facets of LDLR biology that remain unexplored. This review will focus on pathways that regulate the LDLR and emerging concepts of LDLR biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208925</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323578>10.1161/CIRCRESAHA.124.323578</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208925</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Heidi M Schmidt</dc:creator>
<dc:creator>Kelsey E Jarrett</dc:creator>
<dc:creator>Thomas Q de Aguiar Vallim</dc:creator>
<dc:creator>Elizabeth J Tarling</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Pathways and Molecular Mechanisms Governing LDL Receptor Regulation</dc:title>
<dc:identifier>pmid:40208925</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323578</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208924/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11;136(8):803-805. doi: 10.1161/RES.0000000000000713. Epub 2025 Apr 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208924/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208924</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000713>10.1161/RES.0000000000000713</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208924</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:40208924</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000713</dc:identifier>
</item>
<item>
<title>Patient-prosthesis mismatch after aortic valve replacement: one size does not fit all</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 10:ehaf200. doi: 10.1093/eurheartj/ehaf200. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208249</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf200>10.1093/eurheartj/ehaf200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208249</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Francesco Zito</dc:creator>
<dc:creator>Reda Rhellab</dc:creator>
<dc:creator>Adine R de Keijzer</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Patient-prosthesis mismatch after aortic valve replacement: one size does not fit all</dc:title>
<dc:identifier>pmid:40208249</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf200</dc:identifier>
</item>
<item>
<title>Expanding CAD assessment beyond coronary arteries: can body composition offer valuable insights?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208238/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 10:ehaf143. doi: 10.1093/eurheartj/ehaf143. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208238/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208238</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf143>10.1093/eurheartj/ehaf143</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208238</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Mouaz Al-Mallah</dc:creator>
<dc:creator>Mahmoud Al Rifai</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Expanding CAD assessment beyond coronary arteries: can body composition offer valuable insights?</dc:title>
<dc:identifier>pmid:40208238</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf143</dc:identifier>
</item>
<item>
<title>Exercise-based cardiac rehabilitation: the importance of home-based approaches</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 10:ehaf202. doi: 10.1093/eurheartj/ehaf202. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf202>10.1093/eurheartj/ehaf202</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208237</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Rod S Taylor</dc:creator>
<dc:creator>Amy Blakemore</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise-based cardiac rehabilitation: the importance of home-based approaches</dc:title>
<dc:identifier>pmid:40208237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf202</dc:identifier>
</item>
<item>
<title>Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention†</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208236/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among statin-treated patients undergoing PCI, residual inflammation but not cholesterol risk was associated with an increased risk of MACE during follow-up.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 10:ehaf196. doi: 10.1093/eurheartj/ehaf196. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Elevated LDL-cholesterol levels and inflammation, as assessed by high-sensitivity C-reactive protein, correlate with cardiovascular risk. However, data on the relative impact of residual LDL-cholesterol and inflammatory risk among statin-treated patients undergoing percutaneous coronary intervention (PCI) is lacking. Hence, this study aimed to investigate the impact of residual cholesterol/inflammatory risk in patients on statin therapy undergoing PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 2012 to 2022, patients at a tertiary centre undergoing PCI were analysed. Patients were stratified according to LDL-cholesterol (≥70 vs &lt;70 mg/dL) and high-sensitivity C-reactive protein (≥2 vs &lt;2 mg/L) levels: no residual cholesterol or inflammatory risk, residual cholesterol risk, residual inflammatory risk, and combined residual cholesterol and inflammatory risk. Patients presenting with acute myocardial infarction, cancer, no statin treatment at admission, or high-sensitivity C-reactive protein levels >;10 mg/L were excluded. The primary endpoint was major adverse cardiovascular events (MACEs), defined as the composite of all-cause mortality, spontaneous myocardial infarction, and stroke 1 year after the index PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 15 494 patients were included. After 1-year follow-up, individuals with isolated residual inflammatory risk had the highest MACE rate (5.1%), followed by patients with combined cholesterol and inflammatory risk, no residual risk, and isolated residual cholesterol risk. After multivariable Cox regression analysis, patients with residual inflammatory risk had a 1.8-fold higher risk for MACE (adjusted hazard ratio: 1.78, 95% confidence interval 1.36-2.33, P &lt; .001) compared with those with no residual cholesterol or inflammatory risk. This was similar in patients with combined residual cholesterol and inflammatory risk (adjusted hazard ratio: 1.56, 95% confidence interval 1.19-2.04, P = 0.001). Of note, no independent association of isolated residual cholesterol risk (adjusted hazard ratio: 1.01, 95% confidence interval .76-1.35, P-value = .920) with MACE was noted (P-trend across all groups &lt;.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among statin-treated patients undergoing PCI, residual inflammation but not cholesterol risk was associated with an increased risk of MACE during follow-up.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208236</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf196>10.1093/eurheartj/ehaf196</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208236</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Bay</dc:creator>
<dc:creator>Richard Tanner</dc:creator>
<dc:creator>Michael Gao</dc:creator>
<dc:creator>Angelo Oliva</dc:creator>
<dc:creator>Samantha Sartori</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Mauro Gitto</dc:creator>
<dc:creator>Kenneth F Smith</dc:creator>
<dc:creator>Francesca Maria Di Muro</dc:creator>
<dc:creator>Amit Hooda</dc:creator>
<dc:creator>Joseph Sweeny</dc:creator>
<dc:creator>Parasuram Krishnamoorthy</dc:creator>
<dc:creator>Pedro Moreno</dc:creator>
<dc:creator>Prakash Krishnan</dc:creator>
<dc:creator>George Dangas</dc:creator>
<dc:creator>Annapoorna Kini</dc:creator>
<dc:creator>Samin K Sharma</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention†</dc:title>
<dc:identifier>pmid:40208236</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf196</dc:identifier>
</item>
<item>
<title>Gain-of-function enhancer variant near KCNB1 causes familial ST-depression syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A gain-of-function enhancer variant creates a hyperactive regulatory locus that interacts with the KCNB1 promoter and causes FSTD. This is the first time that KCNB1 has been implicated in human cardiac electrophysiology and arrhythmogenesis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 10:ehaf213. doi: 10.1093/eurheartj/ehaf213. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Familial ST-depression syndrome (FSTD) is a recently identified inherited cardiac disease associated with arrhythmias and systolic dysfunction. The underlying genetic aetiology has remained elusive. This study aimed at finding the causative variant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 67 FSTD patients (20 families) were studied. Linkage analysis and whole-genome sequencing (WGS) were initially performed. An identified non-coding variant was functionally characterized in AC16 human cardiomyocytes, muscle tissue, and human myocardium. In silico analyses, luciferase and dCas9-activator/repressor assays, protein-DNA experiments, chromosome conformation capture (4C), and RNA sequencing were also performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The electrocardiographic (ECG) phenotype was inherited in an autosomal dominant manner in all families. Linkage analysis revealed a single peak on chromosome 20, and WGS identified a single, rare, non-coding variant located 18 kb downstream of KCNB1 on chromosome 20 in all affected individuals. Perfect co-segregation with the ECG phenotype was observed together with full penetrance in all families. The variant creates a MEF2-binding site and presence of the variant allele or MEF2 co-expression enhanced transcriptional activity. dCas9-activator/repressor assays showed that KCNB1 was the only gene consistently regulated by the locus and 4C experiments in AC16 cells and human muscle tissue confirmed the locus-KCNB1 promoter interaction. Expression analysis in human endocardial tissue did not document any change in gene expression likely explained by expressional heterogeneity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A gain-of-function enhancer variant creates a hyperactive regulatory locus that interacts with the KCNB1 promoter and causes FSTD. This is the first time that KCNB1 has been implicated in human cardiac electrophysiology and arrhythmogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208226</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf213>10.1093/eurheartj/ehaf213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208226</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Alex Hørby Christensen</dc:creator>
<dc:creator>Gang Pan</dc:creator>
<dc:creator>Rasmus L Marvig</dc:creator>
<dc:creator>Francisco German Rodriguez Gonzalez</dc:creator>
<dc:creator>Christoffer Rasmus Vissing</dc:creator>
<dc:creator>Elvira Silajdzija</dc:creator>
<dc:creator>Rasmus Frosted</dc:creator>
<dc:creator>Etsehiwot Girum Girma</dc:creator>
<dc:creator>Migle Gabrielaite</dc:creator>
<dc:creator>Henrik Kjærulf Jensen</dc:creator>
<dc:creator>Kasper Rossing</dc:creator>
<dc:creator>Finn Lund Henriksen</dc:creator>
<dc:creator>Niels Christian Foldager Sandgaard</dc:creator>
<dc:creator>Gustav Ahlberg</dc:creator>
<dc:creator>Jonas Ghouse</dc:creator>
<dc:creator>Pia Rengtved Lundegaard</dc:creator>
<dc:creator>Joachim Weischenfeldt</dc:creator>
<dc:creator>Claes Wadelius</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gain-of-function enhancer variant near KCNB1 causes familial ST-depression syndrome</dc:title>
<dc:identifier>pmid:40208226</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf213</dc:identifier>
</item>
<item>
<title>The American College of Cardiology: Never Wavering in the Pursuit of Excellence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40208162/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 2:S0735-1097(25)05876-0. doi: 10.1016/j.jacc.2025.03.480. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40208162/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40208162</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.480>10.1016/j.jacc.2025.03.480</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40208162</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The American College of Cardiology: Never Wavering in the Pursuit of Excellence</dc:title>
<dc:identifier>pmid:40208162</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.480</dc:identifier>
</item>
<item>
<title>High-Throughput Echocardiography-Guided Induction of Myocardial Ischemia/Reperfusion in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40207377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250411101140&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Echocardiography-guided induction of myocardial IR enables high-throughput induction of myocardial IR injury with precise echocardiographic definition of the occlusion level and immediate evaluation of cardiac function during ischemia. The method provides a more clinically relevant assessment of IR sequelae and offers notable animal welfare advantages by eliminating the need for ventilation and thoracotomy, thereby mitigating potential surgery-related confounders.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 10. doi: 10.1161/CIRCRESAHA.125.326156. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mouse models of myocardial ischemia with subsequent heart failure are common approaches to examine heart failure pathology and possible treatment strategies. We sought to establish a high-throughput approach for echocardiography-guided induction of myocardial ischemia/reperfusion (IR) in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: After visualization of the left coronary artery with high-resolution ultrasound imaging and echocardiographic definition of the level of coronary occlusion, the left anterior descending artery was temporarily occluded with 2 micromanipulator-controlled needles. Functional and molecular changes were assessed and compared with commonly performed surgical techniques.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Echocardiography-guided induction of myocardial IR enabled standardized induction of myocardial IR injury with subsequent left ventricular remodeling. Incorporation of various quality control measures throughout the procedure ensured a high success rate and the absence of relevant postinterventional mortality in experienced hands. Compared with surgical approaches, echocardiography-guided induction of myocardial IR showed a quicker recovery time and induced a less pronounced inflammatory response characterized by decreased local and systemic neutrophil counts. Notably, infarct size and subsequent post-myocardial infarction cardiac dysfunction were comparable between methods. The novel procedure was successfully implemented at different academic institutions with imaging expertise and demonstrated high interinstitutional reproducibility.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Echocardiography-guided induction of myocardial IR enables high-throughput induction of myocardial IR injury with precise echocardiographic definition of the occlusion level and immediate evaluation of cardiac function during ischemia. The method provides a more clinically relevant assessment of IR sequelae and offers notable animal welfare advantages by eliminating the need for ventilation and thoracotomy, thereby mitigating potential surgery-related confounders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40207377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250411101140&v=2.18.0.post9+e462414">40207377</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.125.326156>10.1161/CIRCRESAHA.125.326156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40207377</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Florian Sicklinger</dc:creator>
<dc:creator>Niklas Hartmann</dc:creator>
<dc:creator>Attila Kovacs</dc:creator>
<dc:creator>Carla Weinheimer</dc:creator>
<dc:creator>Jess Nigro</dc:creator>
<dc:creator>Tobias Thiemann</dc:creator>
<dc:creator>Junedh Amrute</dc:creator>
<dc:creator>David Schumacher</dc:creator>
<dc:creator>Moritz Kornardt</dc:creator>
<dc:creator>Laura M Wienecke</dc:creator>
<dc:creator>Lennart Rompel</dc:creator>
<dc:creator>Johannes Fischer</dc:creator>
<dc:creator>John Bachman</dc:creator>
<dc:creator>Olivia Bedard</dc:creator>
<dc:creator>Shibali Das</dc:creator>
<dc:creator>Tim C Kuhn</dc:creator>
<dc:creator>Mirko Völkers</dc:creator>
<dc:creator>Ralf P Brandes</dc:creator>
<dc:creator>Rafael Kramann</dc:creator>
<dc:creator>Nadia Rosenthal</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>Kory J Lavine</dc:creator>
<dc:creator>Florian Leuschner</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>High-Throughput Echocardiography-Guided Induction of Myocardial Ischemia/Reperfusion in Mice</dc:title>
<dc:identifier>pmid:40207377</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.125.326156</dc:identifier>
</item>





























</channel>
</rss>